Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met The Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
Revelation Biosciences Inc. Receives Invitation to give an Oral Presentation at The 29th International
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split effective January 25, 2024
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023
Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies
Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023
REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders
Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress
Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board
